Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced the filing of a new U.S. provisional patent application designed to expand intellectual property protection surrounding Ultrasome™, the Company’s proprietary cell-free regenerative medicine platform.

The newly filed application builds upon Creative Medical’s existing regenerative medicine intellectual property and seeks protection across multiple aspects of the Ultrasome platform, including proprietary product composition, biological potency, manufacturing and quality-control methodologies, stability characteristics, delivery approaches and therapeutic applications.